- Home
- ELMD vs TGTX Comparison
ELMD vs TGTX Comparison
Compare ELMD & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELMD
- TGTX
- Stock Information
- Founded
- ELMD 1992
- TGTX 1993
- Country
- ELMD United States
- TGTX United States
- Employees
- ELMD N/A
- TGTX N/A
- Industry
- ELMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ELMD Health Care
- TGTX Health Care
- Exchange
- ELMD Nasdaq
- TGTX Nasdaq
- Market Cap
- ELMD N/A
- TGTX 5.4B
- IPO Year
- ELMD 2010
- TGTX 1995
- Fundamental
- Price
- ELMD $29.60
- TGTX $30.92
- Analyst Decision
- ELMD
- TGTX Strong Buy
- Analyst Count
- ELMD 0
- TGTX 6
- Target Price
- ELMD N/A
- TGTX $40.67
- AVG Volume (30 Days)
- ELMD 95.6K
- TGTX 2.0M
- Earning Date
- ELMD 02-11-2025
- TGTX 02-26-2025
- Dividend Yield
- ELMD N/A
- TGTX N/A
- EPS Growth
- ELMD 94.54
- TGTX N/A
- EPS
- ELMD 0.72
- TGTX N/A
- Revenue
- ELMD $57,060,000.00
- TGTX $264,790,000.00
- Revenue This Year
- ELMD $14.27
- TGTX $44.11
- Revenue Next Year
- ELMD N/A
- TGTX $63.92
- P/E Ratio
- ELMD $41.14
- TGTX N/A
- Revenue Growth
- ELMD 14.73
- TGTX 39.53
- 52 Week Low
- ELMD $9.81
- TGTX $12.84
- 52 Week High
- ELMD $31.31
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- ELMD 57.61
- TGTX 46.32
- Support Level
- ELMD $28.10
- TGTX $29.90
- Resistance Level
- ELMD $30.58
- TGTX $33.55
- Average True Range (ATR)
- ELMD 1.31
- TGTX 1.75
- MACD
- ELMD 0.02
- TGTX -0.39
- Stochastic Oscillator
- ELMD 79.65
- TGTX 17.45
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.